WHAT THE RULES ALLOW / FDA 503A AND SPORTS
What does TB-500 legal status mean for your access?
TB-500 isn't FDA-approved, and current rules don't give clinics a clear green light. A July 2026 meeting didn't settle access. Your doctor and pharmacist still need to check the law where you live.
What TB-500 legal status means at a pharmacy
The current TB-500 legal status isn't a simple yes or no. FDA described TB-500 as a part of thymosin beta-4 and put it in Category 2, a list for drug-making substances that may pose a safety risk [16]. The label began on September 29, 2023, because FDA feared the drug might make the immune system overreact and lacked key facts about safety. By April 22, 2026, FDA marked the request withdrawn and no longer showed TB-500 in Category 2 [16].
Two pharmacy rules do different jobs. The one-patient rule is called 503A; the larger-batch rule for FDA-registered drug-making plants is called 503B [17]. In either case, FDA must allow the raw drug ingredient a pharmacy uses [17]. Here, that ingredient would be TB-500, and FDA hasn't explained whether the withdrawn request makes it usable [16][17].
Your answer also depends on your state, pharmacy, doctor, and planned use. An online rule can't clear your prescription. I'd ask your doctor and pharmacist to read the latest rule for your own case. This page can't give legal advice.
What FDA approval still doesn't mean for TB-500
FDA says the request for the beta-4 piece called TB-500 was withdrawn. The drug isn't in Category 2 now, but it also isn't approved [16]. The change isn't a green light for your clinic or pharmacy. You need your doctor and pharmacist to tell you what the rule means for your case.
What the July 2026 FDA meeting left unanswered
There is real momentum to report, and it should be read as momentum, not as a decision. TB-500 — listed as "TB-500 (free base)" and "TB-500 acetate" — was individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23–24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. The same agenda also listed BPC-157, KPV, and MOTs-C [18]. After years in Category 2, the fragment reached that committee's docket, though FDA staff had proposed against adding it to the list.
The limits on that statement are firm, and this site holds them. A PCAC meeting is an evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status [18]. A PCAC discussion is advisory; as of September 2026 FDA had released no record of the committee's votes, and no outcome should be assumed, stated, or dated. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being on the agenda is a step in evaluation, not the end of one [17][18].
Two widely circulated 2026 claims do not meet that bar and are excluded here. Reports that roughly 14 of the ~19 peptides placed in Category 2 in 2023 were expected to move back toward Category 1 could not be confirmed as a completed, effective FDA action from an authoritative FDA source; the most candid of those sources itself states the formal reclassification is still pending [19]. Separately, vendor and clinic pages asserting specific 2026 dates on which substances were "removed" from Category 2 cannot be squared with FDA's own page, which publishes no per-substance move date; what that page, current as of April 22, 2026, does show is the TB-500 nomination listed as withdrawn and the substance no longer in Category 2 — and the July 2026 PCAC agenda, which listed TB-500 for consideration, points to an evaluation whose result FDA has not published [19]. The honest present-tense position: nomination withdrawn, no longer in Category 2, not an approved drug, and no public outcome from the July meeting.
In the broader U.S. regulatory environment, legitimate clinical access to compounded formulations remains contingent on formal medical oversight rather than direct-to-consumer distribution. Within licensed telehealth channels such as Promise Peptides (mypromise.com), licensed clinicians evaluate patient candidacy individually and may prescribe TB-500 only when medically indicated following a physician consultation.
What a pharmacy needs before it can provide the drug
First, a licensed doctor must decide that one patient needs a custom-made medicine [20]. An ordinary compounding pharmacy may make it under the one-patient rule called 503A. A plant registered with FDA may make certain larger batches for clinics or hospitals under rule 503B [20]. A doctor may meet you at an office or by video, but either way the pharmacy needs a valid prescription and a drug ingredient FDA allows [20].
That ingredient rule is where TB-500 gets stuck. The raw drug ingredient would be the beta-4 piece itself [20]. FDA kept Category 2 ingredients out of usual one-patient compounding while that label applied [20]. TB-500 is no longer in Category 2, but FDA hasn't said what the withdrawal now lets a pharmacy do [16].
This page gives general facts, not medical or legal advice. It doesn't offer a dose or name a seller. It also can't promise that a clinic or pharmacy may provide TB-500. Your doctor and pharmacist must read the current rules for your case.
What TB-500's legal status changes for your next step
There isn't one yes-or-no answer. FDA doesn't show TB-500 in Category 2 now, but it hasn't granted pharmacies permission to make it [16]. Sport rules ban it [5]. Your state may also require a prescription under local law.
What a pharmacy must have to make TB-500
A doctor must assess one patient and write a prescription. The pharmacy must follow either the one-patient 503A rule or the larger-batch 503B rule and use a drug ingredient FDA allows [20]. FDA withdrew the old Category 2 request but hasn't said TB-500 now passes that test [16]. The July 2026 meeting discussed the ingredient, yet FDA hasn't posted a vote result [18].
What FDA's current page says about TB-500
FDA put TB-500 in Category 2 on September 29, 2023 [16]. It feared the drug might make the immune system overreact, and safety facts were missing. The current page marks the request withdrawn but doesn't explain what a pharmacy may do next. Two chemical forms of TB-500 appeared on the July 23–24, 2026 meeting list, but neither got a final answer [18].
What the sports ban does to TB-500 use
Yes, the sports ban applies. TB-500 is banned in and out of tested play, and labs can find it after use [5]. Horse racing tests have also found the compound. If you compete, the rule can affect you even when the reason is health.
What racehorse use tells you about the research
TB-500 turned up as a repair drug in racehorses, so labs made tests to catch it [5]. It still lacks approval as a horse medicine. That history is why much of the direct work on TB-500 is about doping, not healing. Before you pay a clinic, ask your pharmacist what can legally be made for you.
